Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Merck Does Deals To Develop Vaccines -- WSJ

share with twitter share with LinkedIn share with facebook
share via e-mail
05/27/2020 | 02:48am EDT

By Jared S. Hopkins

Big drugmaker Merck & Co. said it is working on two potential vaccines and an experimental drug against the coronavirus, joining rivals in the frantic search for medicines.

Merck, one of the world's largest pharmaceutical companies by sales, said Tuesday it is acquiring one experimental vaccine as part of the purchase of its Austrian maker, while partnering in the development of a second vaccine candidate and the potential drug.

The Kenilworth, N.J., drugmaker didn't disclose the terms of the deals.

Some 150 coronavirus vaccines are in development world-wide, including at Johnson & Johnson and Pfizer Inc., and more than 350 drugs are in the works or being studied, according to BioCentury, which is tracking the efforts.

Merck is a longtime maker of vaccines and antivirals, including human papillomavirus shot Gardasil. For weeks, the company had been looking inside its own walls for promising Covid-19 candidates, before deciding to pursue programs started elsewhere.

"We looked inside and outside, and the things we found outside were better," Roger Perlmutter, Merck's R&D chief, said in an interview.

Dr. Perlmutter said Merck has specific criteria for a coronavirus vaccine, including that it provide immunity with a single dose so a second shot isn't needed, and that it use a proven technology that can be scaled up readily for manufacture.

For one vaccine, Merck said it is acquiring privately held Themis Bioscience, of Vienna. In March, Themis said it was collaborating with the French nonprofit Institut Pasteur and the University of Pittsburgh on Covid-19 vaccine development. Themis is working to scale up production for clinical trials that could begin within weeks, Dr. Perlmutter said.

Merck's second coronavirus vaccine effort will take the form of a partnership with the scientific-research organization IAVI, whose experimental vaccine uses the same technology that is the basis for Merck's Ebola Zaire virus vaccine, Dr. Perlmutter said.

Merck said it would help IAVI, a New York-based nonprofit, further develop the vaccine, which could begin human testing later this year.

In addition, Merck said it would license the rights to an experimental Covid-19 drug from privately held Ridgeback Biotherapeutics LP of Miami. Merck plans to continue developing the drug, which is entering midstage testing in patients this week, Dr. Perlmutter said.

The drug works like remdesivir from Gilead Sciences Inc., which the U.S. Food and Drug Administration authorized for emergency Covid-19 use on May 1, after a trial showed it shortened hospitalized patients' recovery time.

Merck plans to target the drug at Covid-19 patients who aren't yet severely sick, even if hospitalized, Dr. Perlmutter said.

Chief Executive Ken Frazier said he wouldn't commit to a vaccine being ready within 12 to 18 months, as other companies and public officials have suggested is possible, because of the large clinical trials needed.

"Those take time. There's no two ways about it," he said in an interview. "We will move as rapidly and responsibly as we can, in conjunction with regulators, but I do not see any way around large clinical trials to show whether something is in fact safe and effective across a large population."

Write to Jared S. Hopkins at jared.hopkins@wsj.com

 

Stocks mentioned in the article
ChangeLast1st jan.
GILEAD SCIENCES, INC. -0.70% 76.65 Delayed Quote.18.79%
MERCK & CO., INC. 1.52% 79.44 Delayed Quote.-13.96%
PFIZER LIMITED -0.97% 4139.75 End-of-day quote.-2.00%
PFIZER, INC. 1.39% 35.72 Delayed Quote.-10.08%
THE NEW HOME COMPANY INC. 0.30% 3.4 Delayed Quote.-27.25%
WORLD CO., LTD. 2.05% 1493 End-of-day quote.-44.52%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MERCK & CO., INC.
02:16aMERCK : D.C. Circuit Invalidates HHS Rule Requiring Drug-Price Disclosures In Di..
AQ
07/10MERCK : FDA Grants Priority Review to Merck's Supplemental Biologics License App..
AQ
07/10MERCK : Animal Health Receives U.S. FDA Approval of BRAVECTO Monthly Chews
AQ
07/09MERCK : Animal Health Gets FDA Approval of Bravecto Monthly Chews
DJ
07/09MERCK : Animal Health Receives U.S. FDA Approval of BRAVECTO® (fluralaner) Month..
BU
07/09MERCK : Announces Appointment of Organon and Co. General Counsel
AQ
07/09EISAI : and Merck Receive Complete Response Letter for LENVIMA plus KEYTRUDA Com..
AQ
07/09MERCK : AstraZeneca and Merck - LYNPARZA Approved in the EU for Germline BRCA-mu..
AQ
07/09MERCK : Gets FDA Priority Review of Keytruda in Classical Hodgkin Lymphoma
DJ
07/09MERCK : FDA Grants Priority Review to Merck's Supplemental Biologics License App..
BU
More news
Financials (USD)
Sales 2020 47 325 M - -
Net income 2020 11 117 M - -
Net Debt 2020 14 876 M - -
P/E ratio 2020 18,2x
Yield 2020 3,01%
Capitalization 201 B 201 B -
EV / Sales 2019
EV / Sales 2020 4,55x
Nbr of Employees 71 000
Free-Float 70,5%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 20
Average target price 92,84 $
Last Close Price 79,44 $
Spread / Highest target 34,7%
Spread / Average Target 16,9%
Spread / Lowest Target 1,96%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Sandy Tremps Vice President-R&D IT CIO
Thomas Henry Glocer Independent Director
Leslie A. Brun Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.-13.96%197 511
JOHNSON & JOHNSON1.41%389 709
ROCHE HOLDING AG5.59%300 114
PFIZER, INC.-10.08%195 697
NOVARTIS AG-11.32%191 193
ABBVIE INC.11.67%174 243